×
Don't Miss Out!
Get your weekly Breakfast Briefing eNewsletter, filled with news, trends, and vital information from DIA!
Back to Agenda
Why Does Drug Loss Occur? Challenges to be Addressed for Patients, and Japan's Contribution to Globalized Drug Development
Session Chair(s)
Toshiharu Sano, RPh
Associate Vice President
MSD, Japan
This forum will address need for a global development strategy aimed at enhancing patient access to new drugs and maximizing business opportunities in Japan. The panelists will consist of members from pharma industry associations, agency and academia
Learning Objective : Maximize value of innovative products for the global market including Japan; Apply learnings to clinical development strategy to expand target patients and market effectively; Enhance access to innovative drugs for children and patients with rare diseases; Influence regulators, industry, and trial sites to improve the local environment and reduce burdens in global simultaneous development.
Speaker(s)
Changes in Japan's Pharmaceutical Regulations and Clinical Environment
Representative Invited
Pharmaceuticals and Medical Devices Agency (PMDA), Japan
Initiatives of Medical Institutions - Introduction to High-Quality Trials Using Networks
Kenichi Nakamura, DrMed
National Cancer Center Hospital, Japan
Director, Department of International Clinical Development
What is Drug Lag and Loss: Challenges for Globalization in Japan
Nobutaka Kobayashi, MPharm
Mitsubishi Tanabe Pharma Corporation, Japan
Deputy Director
Have an account?